Oramed 3Q 2026: Revenue $0, EPS $0.43 — 10-Q Summary
Oramed reported no revenue and a 62% decline in net income for 3Q 2026, with net income of $18.41M and EPS of $0.43. The decrease was due to Scilex revaluation losses and other factors, partially offset by Alpha Tau gains and a Scilex fee. Cash reserves were $28.9M, expected to last 12 months.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to depress the stock, with limited upside unless upcoming clinical data changes sentiment.
Market read
Micro‑cap biotech earnings miss with zero revenue; likely triggers sell‑off.
What to watch
Cash balance of $28.9M provides runway for upcoming clinical milestones.
Background
Oramed Pharmaceuticals filed its Q3 2026 10‑Q, reporting zero revenue and a significant earnings decline.
Ticker impact
Q3 2026 revenue was $0 and diluted EPS $0.43, down sharply from prior year.
downward pressure as market prices in weak revenue and earnings decline
Zero revenue and a 62% drop in net income signal operational challenges, prompting investors to reduce exposure.
Market effects
Biotech sector may see broader risk-off sentiment due to weak results.
Limited to U.S. small-cap biotech investors.
Minimal global impact.
Counterpoint
Potential upside if the company successfully advances its POD technology pipeline.
Key entities
- companyOramed Pharmaceuticals Inc.
Biotech firm reporting Q3 2026 results.
